US 12,728,125 B2
Methods for treating neutropenia
E. Lynne Kelley, Boston, MA (US); and Sarah Cohen, Boston, MA (US)
Assigned to X4 Pharmaceuticals, Inc., Boston, MA (US)
Filed by X4 Pharmaceuticals, Inc., Boston, MA (US)
Filed on Jul. 15, 2025, as Appl. No. 19/269,675.
Application 19/269,675 is a continuation of application No. 19/096,210, filed on Mar. 31, 2025, granted, now 12,377,090.
Application 19/096,210 is a continuation of application No. 17/941,509, filed on Sep. 9, 2022, granted, now 12,285,424, issued on Apr. 29, 2025.
Application 17/941,509 is a continuation of application No. PCT/US2021/021713, filed on Mar. 10, 2021.
Claims priority of provisional application 62/987,707, filed on Mar. 10, 2020.
Prior Publication US 2025/0339423 A1, Nov. 6, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4709 (2006.01); A61K 9/00 (2006.01); A61P 7/00 (2006.01)
CPC A61K 31/4709 (2013.01) [A61K 9/0019 (2013.01); A61P 7/00 (2018.01)] 29 Claims
 
1. A method for treating chronic neutropenia, cyclic neutropenia, or congenital neutropenia in a patient in need thereof, wherein the patient does not have a gain-of-function mutation in the CXCR4 gene and has not been diagnosed with WHIM syndrome or with myelokathexis, comprising administering to the patient an effective amount of mavorixafor:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof;
wherein the patient has an absolute neutrophil count (ANC) at or below 1,500 cells/μL at a baseline prior to administering mavorixafor or a pharmaceutically acceptable salt thereof; and the amount of mavorixafor or a pharmaceutically acceptable salt thereof administered is 100 mg/day to 600 mg/day.